PDCD1 and neoplasm: To achieve different anti-tumour efficacy rates, we combined the i.t. administration of the TC-1/A9-immunodominant E7 epitope in the form of a long peptide and/or the TLR-3-ligand PIC with systemic administration of the IC inhibitor anti-PD-1 mAb.